• SEC Filings

REGENXBIO INC. (NASDAQ:RGNX) Files An 8-K Results of Operations and Financial Condition
Item 2.02.

Results of Operations and Financial Condition.

On August 8, 2018, REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended June 30, 2018. The press release is furnished as Exhibit99.1 to this Current Report on Form8‑K and is incorporated by reference herein.

The Company expects to discuss certain presentation materials (the “Presentation Materials”) during its conference call and webcast scheduled to begin at 8:00 a.m. Eastern Time on August 8, 2018. The Presentation Materials are furnished as Exhibit 99.2 to this Current Report on Form 8-K. The Presentation Materials include selected financial information relating to the Company, and the portion of the Presentation Materials including such financial information is incorporated by reference herein.

Item 2.02.Regulation FD Disclosure.

The Presentation Materials described in Item 2.02 above are incorporated by reference herein.

The information in Items2.02 and 7.01 of this Current Report on Form8‑K and Exhibits99.1 and 99.2 attached hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

(d)Exhibits

REGENXBIO Inc. Exhibit
EX-99.1 2 rgnx-ex991_15.htm EX-99.1 rgnx-ex991_15.htm EXHIBIT 99.1   REGENXBIO Reports Second Quarter 2018 Financial and Operating Results and Interim Data from Ongoing Clinical Trials for Wet Age-Related Macular Degeneration and Homozygous Familial Hypercholesterolemia     • Announces positive interim update from RGX-314 Phase I clinical trial for wet AMD   • Provides preliminary interim update from RGX-501 Phase I/II clinical trial for HoFH   • Announces appointment of Dr. Ram Palanki as SVP of Commercial Strategy and Operations   • $306 million in cash,…
To view the full exhibit click here

About REGENXBIO INC. (NASDAQ:RGNX)

REGENXBIO Inc. is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors). Its NAV Technology Platform is applied in the development of approximately 30 product candidates for a range of diseases, including over five internally developed product candidates and approximately 20 partnered product candidates developed by its NAV Technology Licensees. Its therapeutic programs include RGX-501 for Homozygous familial hypercholesterolemia (HoFH); RGX-111 for Mucopolysaccharidosis Type I (MPS I); RGX-121 for Mucopolysaccharidosis Type II (MPS II); RGX-314 for Wet age related macular degeneration (wet AMD), and RGX-321 for X-linked retinitis pigmentosa (XLRP).